Switching to Exenatide for Better Diabetes Control
Author Information
Author(s): Carol Wysham, Richard Bergenstal, Jaret Malloy, Ping Yan, Brandon Walsh, James Malone, Kristin Taylor
Primary Institution: Rockwood Clinic
Hypothesis
Does switching from sitagliptin or pioglitazone to exenatide once-weekly improve glycaemic control and weight in patients with Type 2 diabetes?
Conclusion
Patients who switched to once-weekly exenatide from daily sitagliptin or pioglitazone had improved or sustained glycaemic control, with weight loss.
Supporting Evidence
- Patients who switched from sitagliptin to exenatide once-weekly exhibited a significant reduction in HbA1c.
- Patients switching from pioglitazone to exenatide once-weekly maintained their HbA1c improvements.
- Exenatide once-weekly was generally well tolerated with mostly mild or moderate adverse events.
Takeaway
This study shows that changing from daily diabetes medications to a weekly injection can help people control their blood sugar better and lose weight.
Methodology
Patients were randomized to receive either exenatide once-weekly, sitagliptin, or pioglitazone, and then switched to exenatide in the open-label phase.
Potential Biases
Patients and investigators were not informed of original treatment assignments during the open-label phase.
Limitations
The study was open-label and uncontrolled, which may affect the reliability of the results.
Participant Demographics
Patients were adults with Type 2 diabetes, treated with metformin, and had a baseline HbA1c of 8.5 ± 1.1%.
Statistical Information
P-Value
0.0010
Confidence Interval
−1.9 to −1.3%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website